

## 1. General Information

<b>Cohort ID</b>	5001_15
<b>Title (Study Name)</b>	BioPersMed
<b>Principal investigator</b>	Prof.in Barbara Obermayer-Pietsch, Dr. Nicolas Verheyen
<b>Contact information</b>	<a href="mailto:pm-biobank@medunigraz.at">pm-biobank@medunigraz.at</a>
<b>Funding agency</b>	FFG: COMET

## 2. Description

<p>This cohort comprises a huge number of samples and data collected since 2010 and is still ongoing. The aim is to detect biomarkers of patients at risk for cardiovascular and metabolic diseases. The BioPersMed cohort includes the areas: endocrinology &amp; metabolism and cardiology. In the focus of this cohort: e.g. diabetes, fatty liver disease, osteoporosis, cardiovascular diseases. The biobank specimen comprise plasma, serum, buffy coat and urine stored at -80°C with 24/7 temperature surveillance, as well as the according clinical data including a large set of metabolic, cardiovascular, hormonal and general lab and imaging parameters.</p>
---

## 3. Details

<b>ICD 10/O codes / Healthy</b>	E11; E66; M80; M81; I20-I25; R55; I38; I70; I99; I48, Healthy	
<b>Key words</b>	biomarker, metabolism, cardiology, diabetes, osteoporosis, fatty liver disease, cardiovascular diseases, endocrinology	
<b>Collection / Cohort size</b> 12/2023	356.184 aliquots from 1.017 patients	
<b>Informed Consent (IC)</b>	<input checked="" type="checkbox"/> Broad Biobank IC	
	<input checked="" type="checkbox"/> Specific Study IC	
<b>Status</b>	<input checked="" type="checkbox"/> In progress / compl. date: open	
	<input type="checkbox"/> Completed	
<b>Inclusion criteria</b>	<b>Age distribution</b>	>35
	<b>Sex distribution (f:m)</b>	50:50
	<b>Others</b>	-----
<b>Earliest access</b>	As of now	
<b>Quality-standards</b>	<input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)	
<b>Associated publications / references</b>	<p><u>Cohort profile: 'Biomarkers of Personalised Medicine' (BioPersMed): a single-centre prospective observational cohort study in Graz/Austria to evaluate novel biomarkers in cardiovascular and metabolic diseases.</u> Haudum CW, Kolesnik E, Colantonio C, Mursic I, Url-Michitsch M, Tomaschitz A, Glantschnig T, Hutz B, Lind A, Schweighofer N, Reiter C, Ablasser K, Wallner M, Tripolt NJ, Pieske-Kraigher E, Madl T, Springer A, Seidel G, Wedrich A, Zirik A, Krahn T, Stauber R, Pieske B, Pieber TR, Verheyen N, Obermayer-Pietsch B, Schmidt A. <a href="https://pubmed.ncbi.nlm.nih.gov/35393327/">https://pubmed.ncbi.nlm.nih.gov/35393327/</a></p> <p><u>Urinary C-Peptide to Creatinine Ratio (UCPCR) as Indicator for Metabolic Risk in Apparently Healthy Adults-A BioPersMed Cohort Study.</u></p>	

Reintar S, Pöchhacker M, Obermayer A, Eberhard K, Zirlik A, Verheyen N, von Lewinski D, Scherr D, Hutz B, Haudum CW, Pieber TR, Sourij H, Obermayer-Pietsch B.  
<https://pubmed.ncbi.nlm.nih.gov/37432211/>

AMH in Males: Effects of Body Size and Composition on Serum AMH Levels.

Tandl V, Haudum C, Eberhard K, Hutz B, Foessel I, Kolesnik E, Zirlik A, von Lewinski D, Scherr D, Verheyen N, Pieber T, Obermayer-Pietsch B.  
<https://pubmed.ncbi.nlm.nih.gov/37445513/>

#### 4. Material available (aliquot size) and storage conditions

<b>Material</b>	<input checked="" type="checkbox"/> Serum (1000 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> EDTA plasma (1000 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> EDTA Buffy coat (300 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Li-Hep plasma (400 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Na-Citrate plasma (400 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Urine (1000 µl)	<input checked="" type="checkbox"/> -80°C

**Dokument erstellt** (tt/mm/yyyy):  
22/04/2021

**Letzte inhaltliche Aktualisierung** (tt/mm/yyyy):  
05/08/2024